Biochemist and Nobel laureate, awarded the 2020 Nobel Prize in Chemistry for co-developing CRISPR gene editing.
no scored calls yet — needs a stated position or a categorical verdict, with a matured window vs SPY
epI-editing alters protein production without permanent DNA changes, enabling safe, repeatable treatment for common diseases like high LDL cholesterol; Phase 1 underway and IPO proceeds will advance clinical deployment.
Doudna identifies delivery into the patient's body as a core bottleneck and the next development path for turning CRISPR from ex-vivo procedures into broader therapeutics.
Doudna says AI can help summarize data and improve discovery efficiency, but she does not see chatbots inventing new drug ideas or justifying a claim on future drug sales today.